Impaired renal function and cisplatin-based regimens as risk factors for neoadjuvant chemotherapy-induced acute kidney injury in muscle-invasive bladder cancer: A multicenter retrospective study.

被引：0
|
作者：
Fujita, Naoki
Hosogoe, Shogo
Tanaka, Toshikazu
Ishii, Noritaka
Momota, Masaki
Ito, Hiroyuki
Yoneyama, Takahiro
Ohyama, Chikara
Hatakeyama, Shingo
机构：
[1] Hirosaki Univ, Dept Urol, Grad Sch Med, Hirosaki, Japan
[2] Aomori Prefectural Cent Hosp, Dept Urol, Aomori, Japan
[3] TOWADA CITY HOSP, Dept Urol, TOWADA, Japan
[4] Aomori Rosai Hosp, Dept Urol, Hachinohe, Japan
[5] Tsugaru Gen Hosp, Dept Urol, Goshogawara, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2025年 / 43卷 / 5_SUPPL期
关键词：
D O I：
10.1200/JCO.2025.43.5_suppl.760
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [21] The optimal way to determine kidney function for cisplatin-based neoadjuvant chemotherapy in muscle-invasive bladder cancer: A European Association of Urology young academic urologists urothelial cancer working group multiinstitutional study
    Pichler, R.
    Fritz, J.
    Mari, A.
    Cadenar, A.
    Von Deimling, M.
    Del Giudice, F.
    Leonardo, C.
    Bologna, E.
    Mori, K.
    Rana, T.
    De Santis, M.
    Klatte, T.
    Erber, B.
    Lackner, F.
    Kronbichler, A.
    Fisch, M.
    Moschini, M.
    Pradere, B.
    Mertens, L. S.
    EUROPEAN UROLOGY, 2024, 85 : S872 - S872
  • [22] Re: Genomic Differences Between "Primary" and "Secondary" Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy
    Zuiverloon, Tahlita C. M.
    Theodorescu, Dan
    EUROPEAN UROLOGY, 2019, 75 (04) : 694 - 694
  • [23] OUTCOME OF NON-RESPONDERS TO NEOADJUVANT IMMUNOTHERAPY COMPARED TO CISPLATIN-BASED CHEMOTHERAPY BEFORE RADICAL CYSTECTOMY IN MUSCLE-INVASIVE BLADDER CANCER
    Bandini, Marco
    Zaffuto, Emanuele
    Marandino, Laura
    Scuderi, Simone
    Pederzoli, Filippo
    Raggi, Daniele
    Salonia, Andrea
    Gandaglia, Giorgio
    Comana, Sabrina
    Barletta, Francesco
    Pellegrino, Antony
    Giusy, Burgio
    Moschini, Marco
    Fossati, Nicola
    Briganti, Alberto
    Montorsi, Francesco
    Colombo, Renzo
    Necchi, Andrea
    Gallina, Andrea
    JOURNAL OF UROLOGY, 2020, 203 : E840 - E840
  • [24] Re: Genomic Differences between "Primary" and "Secondary" Muscle-Invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-Based Neoadjuvant Chemotherapy
    Chang, Sam S.
    JOURNAL OF UROLOGY, 2019, 202 (01): : 30 - 30
  • [25] Efficacy of split schedule (SS) vs conventional schedule (CS) neoadjuvant cisplatin-based chemotherapy for muscle-invasive bladder cancer (MIBC)
    Osterman, Chelsea K.
    Babu, Dilip Sankar
    Geynisman, Daniel M.
    Lewis, Bianca
    Somer, Robert A.
    Balar, Arjun Vasant
    Zibelman, Matthew R.
    Guancial, Elizabeth A.
    Narayan, Vivek
    Guzzo, Thomas J.
    Plimack, Elizabeth R.
    Vaughn, David J.
    Fung, Chunkit
    Mamtani, Ronac
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [26] Comparative Effectiveness of Neoadjuvant Pembrolizumab Versus Cisplatin-based Chemotherapy or Upfront Radical Cystectomy in Patients with Muscle-invasive Urothelial Bladder Cancer
    Li, Roger
    Nocera, Luigi
    Rose, Kyle M.
    Raggi, Daniele
    Naidu, Shreyas
    Mercinelli, Chiara
    Cigliola, Antonio
    Tateo, Valentina
    Patane, Damiano
    Grass, G. Daniel
    Gilbert, Scott M.
    Sexton, Wade J.
    Bandini, Marco
    Moschini, Marco
    Briganti, Alberto
    Montorsi, Francesco
    Spiess, Philippe E.
    Necchi, Andrea
    EUROPEAN UROLOGY ONCOLOGY, 2024, 7 (03): : 614 - 624
  • [27] Impact of neoadjuvant chemotherapy-induced acute kidney injury on oncological outcomes in patients who underwent radical cystectomy: A multicenter retrospective study.
    Fujita, Naoki
    Momota, Masaki
    Hatakeyama, Shingo
    Ito, Hiroyuki
    Yoneyama, Takahiro
    Hashimoto, Yasuhiro
    Yoshikawa, Kazuaki
    Ohyama, Chikara
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [28] Utility of Clinical Risk Stratification in the Selection of Muscle-Invasive Bladder Cancer Patients for Neoadjuvant Chemotherapy: A Retrospective Cohort Study
    von Rundstedt, Friedrich-Carl
    Mata, Douglas A.
    Kryvenko, Oleksandr N.
    Shah, Anup A.
    Jhun, Iny
    Lerner, Seth P.
    BLADDER CANCER, 2017, 3 (01) : 35 - 44
  • [29] The utility of neoadjuvant gemcitabine plus carboplatin followed by immediate radical cystectomy in patients with muscle-invasive bladder cancer who are ineligible for cisplatin-based chemotherapy
    Hiromi Murasawa
    Takuya Koie
    Chikara Ohyama
    Hayato Yamamoto
    Atsushi Imai
    Shingo Hatakeyama
    Takahiro Yoneyama
    Yasuhiro Hashimoto
    Ikuya Iwabuchi
    Masaru Ogasawara
    Toshiaki Kawaguchi
    International Journal of Clinical Oncology, 2017, 22 : 159 - 165
  • [30] Defects in DNA Repair Genes Confer Improved Long-term Survival after Cisplatin-based Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer
    Miron, Benjamin
    Hoffman-Censits, Jean H.
    Anari, Fern
    O'Neill, John
    Geynisman, Daniel M.
    Zibelman, Matthew R.
    Kutikov, Alexander
    Viterbo, Rosalia
    Greenberg, Richard E.
    Chen, David
    Lallas, Costas D.
    Trabulsi, Edouard J.
    Alpaugh, R. Katherine
    Dulaimi, Essel
    Golemis, Erica A.
    Uzzo, Robert
    Ross, Eric A.
    Plimack, Elizabeth R.
    EUROPEAN UROLOGY ONCOLOGY, 2020, 3 (04): : 544 - 547
12345